The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
المؤلفون المشاركون
Du, Juan
Lu, Jing
Lu, Jin
Liu, Aijun
Fu, Weijun
Huang, Xiaojun
Chen, Wenming
Hou, Jian
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-11-08
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
The International Staging System (ISS) is the most important prognostic system for multiple myeloma (MM).
It was identified in the era of conventional agents.
The outcome of MM has significantly changed by novel agents.
Thus the applicability of ISS system in the era of novel agents in Chinese patients needs to be demonstrated.
We retrospectively analyzed the clinical outcomes and prognostic significance of ISS system in 1016 patients with newly diagnosed multiple myeloma in Chinese patients between 2008 and 2012, who received bortezomib- or thalidomide-based regimens as first-line therapy.
The median overall survival (OS) of patients for ISS stages I/II/III was not reached/55.4 months/41.7 months (p<0.001), and the median progression-free survival (PFS) was 30/29.5/25 months (p=0.072), respectively.
Statistically significant difference in survival was confirmed among three ISS stages in thalidomide-based group, but not between ISS stages I and II in bortezomib-based group.
These findings suggest that ISS system can predict the survival in the era of novel agents in Chinese MM patients, and bortezomib may have the potential to partially overcome adverse effect of risk factors on survival, especially in higher stage of ISS system.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Lu, Jing& Lu, Jin& Liu, Aijun& Fu, Weijun& Du, Juan& Huang, Xiaojun…[et al.]. 2015. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis. BioMed Research International،Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1057023
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Lu, Jing…[et al.]. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis. BioMed Research International No. 2015 (2015), pp.1-7.
https://search.emarefa.net/detail/BIM-1057023
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Lu, Jing& Lu, Jin& Liu, Aijun& Fu, Weijun& Du, Juan& Huang, Xiaojun…[et al.]. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-7.
https://search.emarefa.net/detail/BIM-1057023
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1057023
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر